Increased gap junctional intercellular communication is directly related to the anti-tumor effect of all-trans-retinoic acid plus tamoxifen in a human mammary cancer cell line

Journal of Cellular Biochemistry

Volumn 89, Issue 3, 2003, Pages 450-461

  Sáez, Claudia G ^a   Velasquez L ^a   Montoya, M ^a   Eugenin E ^a   Alvarez, M G ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Anti tumor; Chemoprevention; Gap junctional intercellular communication; Human breast cancer cells

Indexed keywords

GAP JUNCTION PROTEIN; GLYCYRRHETINIC ACID; MYC PROTEIN; PROTEIN BCL 2; RETINOIC ACID; TAMOXIFEN; TELOMERASE; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL COMMUNICATION; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; GAP JUNCTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CADHERINS; CELL COMMUNICATION; GAP JUNCTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TAMOXIFEN; TELOMERASE; TRETINOIN; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0038699057     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10519     Document Type: Article

References (38)

1. Bruzzone R, White TW, Paul DL. 1993. Connections with Connexins: The molecular basis of direct intercellular signaling. Eur Biochem 238:1.
2. Choi SH, Kang HK, Im EO, Kim YJ, Bae YT, Choi YH, Lee KH, Chung HY, Chang HK, Kim ND. 2000. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by retinoic acids. Int J Oncol 17:971-976.
3. DeoCampo ND, Wilson MR, Trosko JC. 2000. Cooperation of bcl-2 and myc in the neoplastic transformation of normal rat liver epithelial cells is related to the down-regulation of gap junction mediated intercellular communication. Carcinogenesis 21:1501-1506.
4. Ding Z, Green AG, Yang X, Chernenko G, Tang SC, Pater A. 2002. Retinoic acid inhibits telomerase activity and down-regulates expression but does not affect splicing of hTERT: Correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis-multidrug-resistance model. Exp Cell Res 272:185-191.
5. Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC. 1991. Involvement of gap junctions in tumorigenesis: Transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA 88:10701-10705.
6. Fanidi A, Harrington EA, Evan GI. 1992. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556.
7. Fontana JA, Mezo AB, Cooper BN, Miranda D. 1990. Retinoid modulation of estradiol-stimulated growth and of protein synthesis and secretion in human breast cancer cells. Cancer Res 50:1997-2002.
8. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A. 1993. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 142:987-993.
9. Goodenough DA, Golier JA, Paul DL. 1996. Connexins, connexons, and intercellular communication. Ann Rev Biochem 65:475.
10. Hackett JA, Greider CW. 2002. Balancing instability: Dual roles for telomerase and telomere dysfunction in tumor-igenesis. Oncogene 21:619-626.
11. Herbert BS, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, Shay JW. 2001. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst 93: 39-45.
12. Hirschi KK, Xu CE, Tsukamoto T, Sager R. 1996. Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ 7:861-870.
13. Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G, Wallwiener D. 1998. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer 79:8-12.
14. Huang RP, Hossain MZ, Gano J, Fan Y, Boyton AL. 2001. Connexin 43 (Cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 92: 130-138.
15. Kang Y, Cortina R, Perry RR. 1996. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst 88:279-284.
16. Koskinen PS, Alitalo K. 1993. Role of myc amplification and over-expression in cell growth, differentiation and death. Semin Cancer Biol 4:3-12.
17. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M. 1999. Estrogen activates telomerase. Cancer Res 59:5917-5921.
18. Lowenstein WR. 1979. Junctional intercellular communication and the control of growth. Biochim Biophys Acta 560:1.
19. Lowenstein WR, Kanno Y. 1966. Intercellular communication and the control of growth: Lack of communication between cells. Nature (Lond) 209:1248-1249.
20. Mehta PP, Bertran JS, Lowenstein WR. 1986. Growth inhibition of transformed cells correlates with their junctional communication with normal cells. Cell 44:187-196.
21. Mehta PP, Bertran JS, Lowenstein WR. 1989. The action of retinoids on cellular growth correlate with their action on gap junctional communication. J Cell Biol 108:1053-1065.
22. Mehta PP, Hotz-Wagenblatt A, Rose B, Shalloway D, Lowenstein WR. 1991. Incorporation of the gene for cell-cell channel protein into transformed cells leads to normalization of growth. J Membr Biol 124:207-225.
23. Mesnil M, Yamasaki H. 2000. Bystander effect in herpes simplex virus-thymidine kinase/gaciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res 60:3989-3999.
24. Nayfield SG. 1995. Tamoxifen's role in chemoprevention of breast cancer: An update. J Cell Biochem Suppl 22: 42-50.
25. Perry RR, Kang Y, Greaves B. 1995. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and-independent human breast cancer cells. Ann Surg Oncol 2: 238-284.
26. Reed JC. 1994. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6.
27. Rogers M, Berestcky JM, Hossain MZ, Guo H, Kadle R, Nicholson BJ, Bertram JS. 1990. Retinoid enhanced gap junctional communication is achieved by increased levels of connexin43 mRNA and protein. Mol Carcinog 3:335-343.
28. Shang Y, Baumruckers CR, Green MH. 1998. c-Myc is a mayor mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells. J Biol Chem 273:30608-30613.
29. Sporn MB, Roberts AB. 1983. Role of retinoids in differentiation and carcinogenesis. Cancer Res 43:3034-3040.
30. Sáez JC, Berthoud VM, Moreno AP, Spray DC. 1993. Gap junctions: Multiplicity of controls in differentiated and undifferentiated cells and possible functional implications. Adv Second Messengers Phosphoproteins Res 27: 16-198.
31. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W. 1997. Effects of alltrans retinoic acid and 13-cis-retinoic acid on breastcancer cell lines: Growth inhibition and apoptosis induction. Int J Cancer 70:619-627.
32. Trosko JE, Madhukar BV, Chang CC. 1993. Endogenous and exogenous modulation of gap junctional intercellular communication: Toxicological and pharmacological implications. Life Sci 53:1-19.
33. Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, Nakamura M, Koike K, Ohmichi M, Inoue M. 2002. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 21:3517-4524.
34. Watanabe J, Nomata K, Noguchi M, Satoh H, Kanda S, Kanetake H, Saito Y. 1999. All-trans retinoic acid enhances gap junctional intercellular communication among renal epithelial cells in vitro treated with renal carcinogens. Eur J Cancer 35:1003-1008.
35. Yamasaki H. 1990. Gap junctional intercellular communication and carcinogenesis. Carcinogenesis 11:1051-1058.
36. Yamasaki H, Nauss CG. 1996. Role of connexin genes in growth control. Carcinogenesis (Lond) 17:1199-1213.
37. Zhang L-X, Cooney RV, Bertran JS. 1992. Carotenoids up-regulate connexin 43 gene expression independent of their provitamin a or antioxidant properties. Cancer Res 52:5707-5712.
38. L, without alteration of p53 protein levels. Clin Cancer Res 5:2971-2977.